Calcium Bilirubinate at the Randall's Plaque-Kidney Stone Interface: First Description

Red-orange crystals in 1.1% of Randall's plaque stones were identified as calcium bilirubinate — a bile pigment — possibly linked to liver disease.

Journal: Journal of Nephrology | Published: 2026-06-04 | Type: Journal Article | PMID: 41955276 Authors: Van de Perre E (UZ Brussel), Bazin D, Boury A (CNRS/Institut de Chimie Physique), Wissing KM (UZ Brussel), Borondics F (SOLEIL Synchrotron), Daudon M, Letavernier E (Hôpital Tenon, AP-HP) Funding/COI: Funding not listed. All authors declare no competing interests.

Summary

Researchers retrospectively reviewed 44,213 intact kidney stones analyzed at French and Belgian centers over 34 years and found that 1.1% of stones bearing Randall's plaque had visible red/orange deposits at the plaque–stone interface. Using Fourier-transform infrared spectroscopy with synchrotron light, they identified those deposits in one stone as calcium bilirubinate — a bile pigment not previously reported at this anatomical site. The absence of iron on energy-dispersive X-ray analysis rules out hemosiderin as an alternative explanation, but the clinical significance of the finding remains entirely unknown.

Claims

• 44,213 intact kidney stones underwent morpho-constitutional analysis between 1989 and 2023
• 28.5% (12,587) exhibited a Randall's plaque
• 1.1% (142) of plaque-bearing stones had red/orange deposits at the plaque or plaque–stone interface
• Scanning electron microscopy of two stones showed sharp-edged, polygonal prismatic crystal morphology
• FTIR spectroscopy of one stone confirmed the deposits as calcium bilirubinate
• Energy-dispersive X-ray absorptiometry of one stone showed no iron — ruling out hemosiderin
• Authors hypothesize a possible association with underlying hepatic or biliary disease, but present no patient-level data to support it

Study Quality

The prevalence estimate (1.1% of Randall's plaque stones) is built on a large and credible dataset — 34 years of morpho-constitutional stone analysis is unusual in the literature. The analytical chemistry is serious: synchrotron FTIR from SOLEIL is a high-sensitivity technique appropriate for trace mineral identification. However, the chemical characterization was performed on a total of one to two stones — FTIR composition was confirmed in exactly one. Generalizing a compositional claim from n=1 is a significant methodological limitation regardless of technique quality. No patient-level clinical data (diagnosis, liver function, biliary history) are reported for any of the 142 affected cases, which means the hepatic/biliary hypothesis is entirely unsupported by the data presented.

Red Flags

• FTIR compositional identification rests on a single stone; SEM on two
• No clinical data on any of the 142 patients — the hypothesized biliary/hepatic link has zero evidential support in this paper
• Retrospective database review with no matched controls
• Funding source not disclosed
• Causal pathway from bile pigment to stone nucleation is not proposed, let alone tested
• Cannot determine whether calcium bilirubinate deposits are incidental, pathogenic, or a sampling artifact from stone handling

Strengths

• 44,213-stone database over 34 years provides a reliable prevalence denominator
• Synchrotron FTIR is a rigorous analytical method for mineral identification
• Iron-negative EDX definitively excludes hemosiderin as an alternative explanation
• Multi-disciplinary collaboration between clinical nephrology and analytical chemistry groups is appropriate for this type of characterization
• Honest about the limits of their conclusions — the paper does not overclaim

Verdict

This is a small, carefully reported first description that earns its "first description" label — calcium bilirubinate has genuinely not been formally identified at the Randall's plaque interface before. The large database gives the 1.1% prevalence number credibility. Everything else is speculation: the chemistry is confirmed in one stone, the clinical significance is unknown, and the hepatic disease hypothesis is untested. This paper opens a question it cannot answer. It belongs in a literature review on Randall's plaque composition as a footnote, not a citation for a clinical claim.